CDKN2A and breast carcinoma: Luiz Fernando de Queiroz et al. also described a new method to monitor breast cancer patients by monitoring the methylation status of CDKN2A/p16INK4A (cyclin-dependent kinase inhibitor 2A) and RB1 (retinoblastoma transcriptional corepressor 1) using cfDNA.